Raffaele Califano(@caliraf) 's Twitter Profileg
Raffaele Califano

@caliraf

Thoracic Oncologist @TheChristieNHS, Honorary Professor @UoM_DCS .
Member @myesmo Educational Publication WG.
Views are my own
No DMs or medical advice given.

ID:273407022

calendar_today28-03-2011 12:44:56

999 Tweets

951 Followers

457 Following

Prof Lennart Nacke, PhD(@acagamic) 's Twitter Profile Photo

Abstracts are your paper's first impression.

A weak abstract can sink even the best research.

I transformed my abstract game with this 6-step Nature formula
(and you can, too)

Abstracts are your paper's first impression. A weak abstract can sink even the best research. I transformed my abstract game with this 6-step Nature formula (and you can, too)
account_circle
Stephen V Liu, MD(@StephenVLiu) 's Twitter Profile Photo

MARS-2 now The Lancet Respiratory Medicine, Dr Eric Lim et al. Phase 3 trial of extended pleurectomy decortication then chemo vs chemo alone in pleural . Survival 19.3m with surgery and 24.8m with no surgery. Surgery arm also had more serious adverse events.
thelancet.com/journals/lanre…

account_circle
ESMO - Eur. Oncology(@myESMO) 's Twitter Profile Photo

authors & readers Ana Bosch, Luka Dobovišek, Daniela Robles @daniela-oaks.bsky.social, shed light on their motivations for contributing to & reading ESMO's range of educational books. Get practical, first-hand advice in concise, reader-friendly formats👉ow.ly/C9hY50RvmSX

Ivana Božović

account_circle
Matthew Evison(@MatthewEvison1) 's Twitter Profile Photo

Our paper JTO & JTO CRR evaluating a digital tobacco dependency service for NHS workers - 24/7 specialist support, NRT/vaping supplies home delivered via the app. >1500 NHS workers, 37% chemically validated 12wk abstinence NHS Greater Manchester Make Smoking History | Greater Manchester ASH

jtocrr.org/article/S2666-…

account_circle
Stephen V Liu, MD(@StephenVLiu) 's Twitter Profile Photo

Pooled analysis of 5y outcomes with pembrolizumab + chemotherapy in PD-L1 negative NSCLC JTO & JTO CRR. Includes KEYNOTE 189, 407, and extension studies. With 60.7m f/u, addition of pembro to chemo improves OS (HR 0.64) & PFS (HR 0.66). 5y OS rate 12.5%.

jto.org/article/S1556-…

account_circle
Bishal Gyawali(@oncology_bg) 's Twitter Profile Photo

The most important video I’ve made for early career academics starting to do peer review.
Nobody teaches how to do a good peer review but you are suddenly invited to do a peer review. So how to be a good peer reviewer?
Here is my advice-

youtu.be/ftstYE9hbCI

account_circle
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ(@APassaroMD) 's Twitter Profile Photo

🛎 just published in NEJM our editorial on the groundbreaking ALINA trial, evaluating the role of adjuvant alectinib in patients with resected NSCLC carrying ALK rearrangements.
A major advance for our patients!
🔗nejm.org/doi/full/10.10…

🛎 just published in @NEJM our editorial on the groundbreaking ALINA trial, evaluating the role of adjuvant alectinib in patients with resected NSCLC carrying ALK rearrangements. A major advance for our patients! 🔗nejm.org/doi/full/10.10…
account_circle
Stephen V Liu, MD(@StephenVLiu) 's Twitter Profile Photo

Among patients without baseline brain metastases, incidence of brain metastases at 5 years was 42.3%. Stresses importance of routine CNS imaging for pts with mutant NSCLC to detect these early and the need for better CNS control with our regimens.

Among patients without baseline brain metastases, incidence of brain metastases at 5 years was 42.3%. Stresses importance of routine CNS imaging for pts with #EGFR mutant NSCLC to detect these early and the need for better CNS control with our regimens.
account_circle
ESMO - Eur. Oncology(@myESMO) 's Twitter Profile Photo

📢New edition of ' : Essentials for Clinicians' now available. This is mainly addressed towards junior doctors but is also suitable for general oncologists or haematologists who want to stay updated. ow.ly/FGCt50R1lqk
Ivana Božović Raffaele Califano Tania Fleitas Kanonnikoff

📢New edition of '#Lymphomas: Essentials for Clinicians' now available. This #ESMOBook is mainly addressed towards junior doctors but is also suitable for general oncologists or haematologists who want to stay updated. ow.ly/FGCt50R1lqk @bozovicspa @caliraf @tfleitask
account_circle